Synopsis: The share of this company jumped 18 percent after reporting strong Q4 FY26 earnings growth, backed by higher profitability, margin expansion, and a 450 percent final dividend announcement.
The share of this company, which is one of India’s largest vitamins, minerals, and supplements (VMS) companies, manufactures and marketing VMS products for a healthy lifestyle and improved quality of life, gained traction after posting Q4 results.
With a market capitalization of Rs 10,196 crore, Procter & Gamble Health Ltd’s share on Wednesday made a day high of Rs 6,701 per share, up by 18 percent from its previous day’s close price of Rs 5,651.65 per share. The share of the company gave a return of 11 percent over the last year.
Result Overview and Dividend
Fiscal year comparison: revenue from operations increasing by 51 percent to Rs 1,408 crore from Rs 934 crore in FY25. Despite the healthy revenue growth, the operating margin moderated to 32 percent in FY26 from 34 percent in the previous fiscal year.
In terms of profitability, profit before tax rose by 44 percent to Rs 450 crore in FY26 compared to Rs 312 crore in FY25. Net profit also registered solid growth, increasing by 40 percent to Rs 327 crore from Rs 234 crore in the previous year. Meanwhile, EPS improved by 39 percent to Rs 196.94 in FY26 against Rs 141.22 in FY25.
Dividend Announcement: The Board of Directors has recommended a final dividend of Rs 45 per equity share for FY26, representing a 450 percent dividend on the face value of Rs 10 per share. The dividend proposal is subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Q4 Business Highlights
Strong Profit Growth: Procter & Gamble Health Limited reported a PAT of Rs 95 crore in Q4 FY26, registering a strong growth of 55 percent YoY, supported by superior brand-building activities and strengthened supply chain capabilities. The company closed FY26 with a PAT of Rs 327 crore, reflecting a growth of 30 percent over the comparable 12-month period last year.
Product Innovations: During the year, the company expanded its healthcare portfolio with the launch of new products such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream, aimed at addressing evolving consumer healthcare and wellness requirements.
Growth Strategy: The company continued to focus on long-term growth by investing across innovation, consumer communication, supply chain efficiency, and go-to-market capabilities. These strategic investments are expected to strengthen operational performance and support sustainable value creation over the coming years.
About the Company
Procter & Gamble Health Limited is one of India’s largest Vitamins, Minerals, and Supplements (VMS) companies, manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. Formerly Merck Limited, the company was acquired by P&G in 2018 and is headquartered in Mumbai with a major manufacturing facility in Goa.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 450% Dividend: Healthcare Stock Jumps 18% After Posting Strong Q4 Results appeared first on Trade Brains.